Study on New Principles of Treatments in Malignant Hematological Diseases, as Acute and Chronic Lymphocytic Leukemia or Multiple Myeloma
B-cell chronic lymphocytic leukaemia (B-CLL) is one of the most frequent hematologic cancers, affecting the elderly in particular. It’s particularly intriguing because, despite being classified as apathologicalentity and having been studied for decades. The goal of this study is to describe the most recent findings in molecular medicine in terms of therapy for malignant hemopathies that have resulted from the deletion of the P53 gene in the human lymphoma genome. Method: In recent years, it has been demonstrated that Flow Cytometry, Elisa, ICT, and Fluorescence in Situ Hybridization are the best techniques for investigating malignant lymphocytes (FISH). This approach is utilised as an alternative to chromosomal banding, which is a common molecular medicine application. Discussion: Endogenous somatic gene therapy research has recently been a foundation of clinical and therapeutic trials. The DNA is utilised to cure an illness that develops as a result of chromosomal mutations. This approach has been used in the treatment of CLL, acute lymphocytic leukaemia [ALL], and multiple myeloma [MM] in recent years.
Conclusion: The frequencies of P53 gene mutations and deletions in CLL can be classified as individual biomarkers in the proteomic and genomic profile for this kind of leukaemia, which can be used in personalised medicine for focused patient treatment.
Author (S) Details
Department of Molecular Biology, Medicine Faculty, Titu Maiorescu University, Bucharest, Romania.
View Book :- https://stm.bookpi.org/NFMMR-V3/article/view/3138